Please login to the form below

Not currently logged in
Email:
Password:

CAR-T therapy

This page shows the latest CAR-T therapy news and features for those working in and with pharma, biotech and healthcare.

CAR-T player Autolus seeks $100m from follow-on financing

CAR-T player Autolus seeks $100m from follow-on financing

It is earmarking $125m to continue the clinical development of its pipeline, headed by CD19-targeted CAR-T therapy AUTO1 in adult acute lymphoblastic leukaemia (ALL) – a rival to Novartis’ ... in paediatric ALL and diffuse large B cell lymphoma (DLBCL

Latest news

  • Janssen’s CAR-T gains PRIME status in Europe Janssen’s CAR-T gains PRIME status in Europe

    CAR-T therapy is an exciting therapeutic platform that harnesses the patient’s immune system to attack tumour cells,” said Sen Zhuang, VP, oncology clinical development, Janssen Research &Development. ... The CAR-T therapy would complement Janssen's

  • Autolus’ next-gen CAR-T looks promising in ALL Autolus’ next-gen CAR-T looks promising in ALL

    The company presented new data this week at the American Association of Cancer Research (AACR) congress for AUTO1, a CD19 CAR-T cell investigational therapy, which is in testing for adults ... They pointed out that severe CRS is “significantly

  • Oxford Biomedica taps Microsoft to progress gene therapy delivery tech Oxford Biomedica taps Microsoft to progress gene therapy delivery tech

    It’s the approach that is used in Novartis’ Kymriah, a CAR-T therapy that was approved last year for the treatment of those with relapsed or refractory large B-cell ... lymphoma. However, Novartis was a prime example of the complex manufacturing

  • CMS proposes coverage scheme for CAR-T therapies CMS proposes coverage scheme for CAR-T therapies

    for CAR T-cell therapy for cases in which the benefits outweigh the risks,” said CMS Administrator Seema Verma. ... Last year, CMS agreed to reimburse the bulk of Kymriah and Yescarta costs under Medicare Part B, which provides outpatient coverage,

  • AbbVie enters BCMA race with Teneobio deal AbbVie enters BCMA race with Teneobio deal

    pipeline molecules.  Coming to the fore in this race are a group of BCMA-targeting CAR-T candidates from Bluebird Bio, Celgene/Juno and Johnson &Johnson/Legend Biotech. ... Teneobio says its “T-cell engaging cancer therapeutics are of the next wave

More from news
Approximately 4 fully matching, plus 70 partially matching documents found.

Latest Intelligence

  • Cell and gene therapy Cell and gene therapy

    In addition, as Eric Althoff from Swiss pharmaceutical firm Novartis points out, making a patient-specific product like a CAR-T therapy is very different from producing a volume drug. ... In the case of a personalised therapy like CAR-T, the cost of the

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... The follow-up, Ultomiris ALXN1210, is a second-generation PNH

  • Deal Watch October 2018

    radioligands and CAR‐T for cancer. $2.1B. Sale. Aurobindo. NovartIs sold part of Sandoz’s US generics. ... Manufacture and supply of CAR‐T cell therapy, Kymriah, for B‐cell acute lymphoblastic leukaemia.

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Bluebird Bio's chief executive Nick Leschly. Cell and gene therapy made the transition from an interesting but unproven science to medical reality in 2017, with two ‘living medicine’ CAR-T ... Its fourth pipeline candidate is the multiple myeloma

  • No incentive for a cure No incentive for a cure

    These include Kymriah, the pioneering CAR-T cell therapy from Novartis, which demonstrated a remarkable 83% remission rate in children and young adults with B-cell precursor acute lymphoblastic leukaemia. ... One of the biggest questions with a curative

More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Highlights in haematologic malignancy from ASH 2018

    The spotlight shone on Chimeric Antigen Receptor(CAR) T-cell therapy; a transformative approach where the patient’s T cells are harvested and re-engineered to recognise antigens expressed by the ... A reduced risk of relapse was also seen when

  • Training the next generation of biotech leaders

    In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.

  • Innovation in pharma: the highs and lows of the current healthcare economy

    Gene therapies often require a ‘one-time only’ treatment offering life-changing potential to patients with conditions where currently there may be no available therapy at all, for instance, in rare ... Also in cancers: chimeric antigen receptor T

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics